We report on a patient with NF1 microdeletion and clinical manifestations that fulfill the diagnostic criteria for neurofibromatosis type 1 but also presenting features reminiscent of Proteus syndrome.

Keywords:
Neurofibromatosis type I, NF1 microdeletion, Proteus syndrome
1.
Biesecker L: The challenges of Proteus syndrome: diagnosis and management. Eur J Hum Genet 14:1151–1157 (2006).
2.
Biesecker LG, Cohen MM Jr: Misdiagnosis of neurofibromatosis type 1 as Proteus syndrome. Panminerva Med 47:197 (2005).
3.
Blumenthal GM, Dennis PA: PTEN hamartoma tumor syndromes. Eur J Hum Genet 16:1289–1300 (2008).
4.
Cardoso MT, de Carvalho TB, Casulari LA, Ferrari I: Proteus syndrome and somatic mosaicism of the chromosome 16. Panminerva Med 45:267–271 (2003).
5.
Cohen MM Jr: Further diagnostic thoughts about the Elephant Man. Am J Med Genet 29:777–782 (1988).
6.
De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, et al: Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 72:1288–1292 (2003).
7.
Dorschner MO, Sybert VP, Weaver M, Pletcher BA, Stephens K: NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Hum Mol Genet 9:35–46 (2000).
8.
Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, et al: Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat 23:111–116 (2004).
9.
López-Correa C, Brems H, Lázaro C, Marynen P, Legius E: Unequal meiotic crossover: a frequent cause of NF1 microdeletions. Am J Hum Genet 66:1969–1974 (2000).
10.
Lu-Emerson C, Plotkin SR: The Neurofibromatoses. Part 1: NF1. Rev Neurol Dis 6:E47–E53 (2009).
11.
Upadhyaya M, Ruggieri M, Maynard J, Osborn M, Hartog C, et al: Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. Hum Genet 102:591–597 (1998).
12.
Zhou X, Hampel H, Thiele H, Gorlin RJ, Hennekam RC, et al: Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 358:210–211 (2001).
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.